RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma PDAC

Brief Summary

Type:
Pancreatic

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT07252232

Study #:
STUDY00162172

Start Date:
May 08, 2026

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT07252232

View Complete Trial Details & Eligibility at ClinicalTrials.gov